• Gilead Chooses AWS, Illumina, Sequoia Fund Chinese Startups, More

    Nov 30 | Bio-IT World | Illumina powers the Canadian COVID-19 Genomics Network, organ-on-a-chip explores infectious disease, and cell analysis acquisitions. Plus new products from PerkinElmer, Bio-Rad, Roswell Biotechnologies, Genialis, and more. More

  • Building the Data Foundation for Faster Time to Science in Healthcare

    Nov 23 | Bio-IT World | Genomics and artificial intelligence (AI) are key to this quest and at-scale advancement of personalized medicine. Both, however, require liquid data and modern data infrastructure that re-imagines the role of data and how it is used. More

  • Gut Microbiome Linked To Aggressive Prostate Cancer

    Nov 22 | Bio-IT World | Evidence has been mounting for decades that what men eat can lower or raise their risk of prostate cancer—including aggressive forms of the disease that can be lethal. But that’s only part of the story. More

  • Biopharma’s Dark Data Problem

    Nov 19 | Bio-IT World | Worldwide spending on pharmaceutical R&D will reach $230 billion by 2026. So with investment dollars flowing in and R&D continuing an upward trajectory all should be well, right? Well… not exactly. Like many industries, pharmaceutical companies are facing a data problem—a dark data problem. More

  • Recursion’s Vision for the New Shape of Drug Discovery

    Nov 17 | Bio-IT World | As a “digital native,” Recursion is working to reshape the drug discovery industry—quite literally. Gone is the vision of a traditional discovery funnel, wide at the top and slowly narrowing. Instead, Recursion proposes a drug discovery machine powering a T-shaped funnel where many options are considered, but failure is fast and the candidates that advance have a potentially higher likelihood of being a successful treatment. Easier said than done. More

  • Unique Repurposing Approach Identifies Potential Alzheimer’s Disease Drug

    Nov 16 | Bio-IT World | Trials for Alzheimer’s disease (AD) drugs have repeatedly failed with billions of dollars invested. But a new, multidisciplinary drug repurposing model, described in a recent article in Nature Aging, combines drug repurposing with precision medicine, network-based drug targeting, induced pluripotent stem cell (iPSC) technology, and real-world data analysis. More
View more articles
Bio IT World Lead Gen

 
Industry-spotlight

Riffyn’s pioneering cloud system, Riffyn Nexus, delivers 2X faster development cycles and 4X productivity gains to the world’s most advanced scientific R&D organizations. Its process-centric experiment design, data capture, and data analytics overcome the limitations of ELN and LIMS systems. Its adaptive data integration engine delivers results that are always ready for machine learning.
Read more here!

Industry-spotlight

Digital Therapeutics: Taking digital health to a new level
Benchling is the most widely-adopted life sciences R&D cloud. Accelerate, measure, and forecast R&D – from discovery through bioprocessing – all in one place. It’s a fully unified platform that centralizes and standardizes all R&D data, so you can spend less time fighting with legacy software, and more time reaching breakthrough discoveries.
Read more here!